Sotera Health Company (SHC)
| Market Cap | 4.45B +27.2% |
| Revenue (ttm) | 1.19B +7.4% |
| Net Income | 117.79M +374.7% |
| EPS | 0.41 +366.8% |
| Shares Out | 285.17M |
| PE Ratio | 38.24 |
| Forward PE | 15.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,092,471 |
| Open | 15.89 |
| Previous Close | 15.57 |
| Day's Range | 15.54 - 15.91 |
| 52-Week Range | 10.80 - 19.85 |
| Beta | 1.80 |
| Analysts | Buy |
| Price Target | 20.11 (+28.75%) |
| Earnings Date | May 5, 2026 |
About SHC
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion seg... [Read more]
Financial Performance
In 2025, Sotera Health Company's revenue was $1.16 billion, an increase of 5.74% compared to the previous year's $1.10 billion. Earnings were $77.95 million, an increase of 75.79%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for SHC stock is "Buy." The 12-month stock price target is $20.11, which is an increase of 28.75% from the latest price.
News
Sotera Health initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Sotera Health (SHC) with a Buy rating and $20 price target Sotera is a provider of sterilization and lab testing services, serving 40 of the…
Sotera Health Company Transcript: Jefferies Global Healthcare Conference 2026
A planned CEO transition brings new leadership with continuity in strategy and growth focus. Business segments show resilience and recovery, with supply chain investments and cross-selling initiatives supporting future performance. Litigation and financial outlook remain stable and well-managed.
Sotera Health Company Transcript: AGM 2026
The meeting covered board updates, strong financial growth, and approval of all proposals, including director elections, executive compensation, and auditor ratification. Strategic focus remains on integrated healthcare solutions and sustained above-market growth.
Sotera Health Company Transcript: RBC Capital Markets Global Healthcare Conference 2026
Leadership transition brings a new CEO with strong med device experience. Sterigenics and Nelson Labs segments show robust demand and margin recovery, supported by new capacity and regulatory-driven growth. Legal wins and a broadened shareholder base position the company for continued momentum.
Sotera Health announces offering of 31.84M shares of common stock for holders
Sotera Health (SHC) Company announced the launch of a secondary offering of 31.84M shares of its common stock. All 31.84M shares are being offered for sale by certain affiliates of…
Sotera Health price target lowered to $22 from $24 at Piper Sandler
Piper Sandler analyst Jason Bednar lowered the firm’s price target on Sotera Health (SHC) to $22 from $24 and keeps an Overweight rating on the shares. The firm notes the…
Sotera Health names Alton Shader as CEO
Sotera Health (SHC) announced the appointment of Alton Shader to the role of CEO of the company, effective May 26, as part of a planned leadership transition. Shader will succeed…
Sotera Health Company Earnings Call Transcript: Q1 2026
Q1 2026 saw 10% revenue growth and 10.5% Adjusted EBITDA growth, with margin expansion and strong segment performance, especially in Nordion. The 2026 outlook was reaffirmed, a CEO transition was announced, and all Georgia bellwether legal cases were dismissed.
Sotera Health Company Earnings release: Q1 2026
Sotera Health Company released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Sotera Health Company Slides: Q1 2026
Sotera Health Company has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Sotera Health Company Quarterly report: Q1 2026
Sotera Health Company has published its Q1 2026 quarterly earnings report on May 5, 2026.
Sotera Health Company Proxy statement: Proxy filing
Sotera Health Company filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
Sotera Health price target lowered to $18 from $20 at Barclays
Barclays lowered the firm’s price target on Sotera Health (SHC) to $18 from $20 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science…
Sotera Health Company Proxy statement: Proxy filing
Sotera Health Company filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Sotera Health Company Proxy statement: Proxy filing
Sotera Health Company filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Sotera Health Company Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
The forum highlighted strong 2025 results, with 5.2% organic revenue growth and margin expansion. 2026 guidance projects continued growth, supported by capacity investments and disciplined capital allocation. Regulatory changes and segment strategies were discussed, with a focus on long-term value creation.
Sotera Health appoints Kenneth Krause to board of directors
Sotera Health Company (SHC) has appointed Kenneth D. Krause as a new independent director to its Board of Directors. Mr. Krause has served as Executive Vice President and CFO of…
Sotera Health Company Transcript: Barclays 28th Annual Global Healthcare Conference
Energy and supply chain risks are well managed with fixed contracts and no current constraints. Strong financial performance in 2025 is expected to continue in 2026, with robust demand for ethylene oxide sterilization and stable pricing. Regulatory and litigation challenges are being addressed proactively.
Sotera Health offers to sell 25M shares of common stock for holders
Sotera Health (SHC) announced the launch of a secondary offering of 25 million shares of its common stock, par value $0.01 per share. All 25 million shares are being offered…
Sotera Health price target raised to $23 from $21 at Citi
Citi analyst Patrick Donnelly raised the firm’s price target on Sotera Health (SHC) to $23 from $21 and keeps a Buy rating on the shares.
Sotera Health price target raised to $23 from $21 at Citi
Citi raised the firm’s price target on Sotera Health (SHC) to $23 from $21 and keeps a Buy rating on the shares. The company established FY26 guidance calling for total…
Sotera Health Company Earnings Call Transcript: Q4 2025
Delivered 20th consecutive year of revenue growth in 2025, with strong margin expansion and cash flow. 2026 guidance calls for 5–6.5% revenue growth and further EBITDA improvement, supported by robust med tech demand and disciplined capital allocation.
Sotera Health Company Annual report: Q4 2025
Sotera Health Company has published its Q4 2025 annual report on February 24, 2026.
Sotera Health Company Earnings release: Q4 2025
Sotera Health Company released its Q4 2025 earnings on February 24, 2026, summarizing the period's financial results.
Sotera Health Company Slides: Q4 2025
Sotera Health Company has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 24, 2026.